Paper Details

  1. Home
  2. Paper Details

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.

Author: GalinskyIlene, HoangCaroline J, McBrideAli, NewmanMatthew J, PaulShilpa, ReliasValerie, RyanJoanne C, SaneeymehriSeyyedeh, StanislausGenique, TobinJennifer

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Glasdegib is a drug used to treat acute myeloid leukemia (AML), a type of blood cancer. This study reviews the use of glasdegib in older adults, who often can't tolerate more intense treatments. The combination of glasdegib and low-dose cytarabine was found to improve survival compared to low-dose cytarabine alone.
Paper Details　
Original Abstract of the Article :
Label="OBJECTIVE" NlmCategory="OBJECTIVE">Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008421/

データ提供：米国国立医学図書館（NLM）

Glasdegib Plus Low-Dose Cytarabine: A Promising Treatment for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a serious blood cancer, particularly challenging to treat in older adults. This study reviews the use of glasdegib, a hedgehog-pathway inhibitor, in combination with low-dose cytarabine (LDAC) as a treatment option for AML in older adults. The researchers reviewed relevant literature and considered practical aspects of treatment for pharmacists and advanced practitioners.

Glasdegib Plus LDAC: Superior Survival Outcomes

The study highlights a randomized phase II study that demonstrated superior overall survival with the combination of glasdegib plus LDAC compared to LDAC alone. This combination therapy offers a promising alternative for older adults with AML who may not be suitable for intensive treatment.

Practical Considerations for Treatment

The researchers discussed practical considerations for treating patients with this combination therapy, including common adverse events (AEs) such as hematologic events, gastrointestinal toxicity, and fatigue. They also emphasized the importance of patient education to facilitate adherence and early AE identification. The study also addressed practical aspects of LDAC delivery, such as dispensing a longer supply to reduce clinic visits.

Dr. Camel's Conclusion

This study is like a desert oasis, offering a new and refreshing approach to treating AML in older adults. The researchers have provided valuable insights into the use of glasdegib plus LDAC, highlighting its potential for improved survival outcomes and practical considerations for effective treatment.

Date :
  1. Date Completed 2021-04-26
  2. Date Revised 2021-04-26
Further Info :

Pubmed ID

33215562

DOI: Digital Object Identifier

PMC8008421

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.